Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
10 participants
INTERVENTIONAL
2017-10-05
2020-07-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension
NCT02108743
Bronchodilator's Effects on Exertional Dyspnoea in Pulmonary Arterial Hypertension
NCT02782052
Airway and Pulmonary Vascular Endothelial Function in Healthy Smokers: Effect of Inhaled Glucocorticosteroid Treatment
NCT02141633
Acute Response of Iloprost Inhalation Using the Breelib Nebulizer in Pulmonary Arterial Hypertension
NCT03365479
Comparison of Vasodilator Response of Inhaled Epoprostenol and Inhaled Nitric Oxide
NCT04231084
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Albuterol followed by placebo
Participants in this group will receive albuterol first followed by Placebo on the next visit
Albuterol
inhalation of 270μg albuterol through a spacer
Placebo
inhalation of placebo through a spacer
Placebo followed by albuterol
Participants in this group will receive placebo first followed by albuterol on the next visit
Albuterol
inhalation of 270μg albuterol through a spacer
Placebo
inhalation of placebo through a spacer
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Albuterol
inhalation of 270μg albuterol through a spacer
Placebo
inhalation of placebo through a spacer
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Regular use of oral pulmonary vasodilators
Exclusion Criteria
* women of childbearing potential who do not use accepted birth- control measures
* pregnant and breast-feeding women
* respiratory infection within 4 weeks of testing
* A systemic systolic arterial BP\> 150 and/or diastolic arterial BP\>100 on the experiment day
* A resting O2 saturation of \< 90%
* Current smoking
* BMI \>35 kg/m2 and/or a diagnosis of obstructive sleep apnea
* Use of inhaled or intravenous pulmonary vasodilators
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Miami
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Adam Wanner
Professor of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adam Wanner, MD
Role: PRINCIPAL_INVESTIGATOR
University of Miami
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Miami
Miami, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20170552
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.